A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
Home
Philip
P
Bagust
Adrian
A
Taylor
Matthew
M
Ambery
Philip
P
Mendes da Costa
Samara
S
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000191:economics; D017048:Health Care Costs; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics* / Q000627:therapeutic use; D018803:Models, Economic; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000191:economics* / Q000627:therapeutic use